Suven Life Sciences Ltd
NSE:SUVEN

Watchlist Manager
Suven Life Sciences Ltd Logo
Suven Life Sciences Ltd
NSE:SUVEN
Watchlist
Price: 117.47 INR -0.53% Market Closed
Market Cap: 25.6B INR
Have any thoughts about
Suven Life Sciences Ltd?
Write Note

Suven Life Sciences Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Suven Life Sciences Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Suven Life Sciences Ltd
NSE:SUVEN
Net Income (Common)
-â‚ą1.5B
CAGR 3-Years
-9%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Divi's Laboratories Ltd
NSE:DIVISLAB
Net Income (Common)
â‚ą16.7B
CAGR 3-Years
-7%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Dishman Carbogen Amcis Ltd
NSE:DCAL
Net Income (Common)
-â‚ą2.5B
CAGR 3-Years
-25%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Syngene International Ltd
NSE:SYNGENE
Net Income (Common)
â‚ą4.8B
CAGR 3-Years
6%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Tarsons Products Ltd
NSE:TARSONS
Net Income (Common)
â‚ą426.4m
CAGR 3-Years
-15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
I
Innova Captab Ltd
NSE:INNOVACAP
Net Income (Common)
â‚ą943.5m
CAGR 3-Years
40%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Suven Life Sciences Ltd
Glance View

Market Cap
25.6B INR
Industry
Life Sciences Tools & Services

Suven Life Sciences Ltd. engages on discovering, developing, and commercializing novel pharmaceutical products which are used in classic therapies. The company is headquartered in Hyderabad, Telangana and currently employs 117 full-time employees. The firm is focused on discovering and developing new chemical entities (NCEs), which are central nervous system therapies for the treatment of cognitive disorders, depressive disorders, sleep disorders, psychiatric disorders, pain and inflammation, gastrointestinal motility disorders. Its research targets include serotonin 6 receptor, serotonin 4 receptor, histamine 3 receptor, Nicotinic acetylcholine (Alpha4beta2) receptor, muscarinic M1 receptor, muscarinic M4 receptor, multimodal and P2X purinoceptor 7 receptor. The company provides a range of Drug Discovery and Development Support Services (DDDSS). The firm offers research services specializing in synthetic, medicinal and analytical chemistry, in-vitro assay development and screening, drug metabolism and pharmacokinetics, toxicology and safety pharmacology, bioanalysis, and NCE formulations.

SUVEN Intrinsic Value
2.1 INR
Overvaluation 98%
Intrinsic Value
Price

See Also

What is Suven Life Sciences Ltd's Net Income (Common)?
Net Income (Common)
-1.5B INR

Based on the financial report for Sep 30, 2024, Suven Life Sciences Ltd's Net Income (Common) amounts to -1.5B INR.

What is Suven Life Sciences Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-8%

Over the last year, the Net Income (Common) growth was -26%. The average annual Net Income (Common) growth rates for Suven Life Sciences Ltd have been -9% over the past three years , -8% over the past five years .

Back to Top